(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 September 2018 (20.09.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/167104 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
C07K 14/55 (2006.01)

(21) International Application Number:
PCT/EP2018/056312

(22) International Filing Date:
13 March 2018 (13.03.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

17161717.8	17 March 2017 (17.03.2017)	EP
1710879.6	06 July 2017 (06.07.2017)	GB
1714429.6	07 September 2017 (07.09.2017)	GB

(71) Applicants: **TUSK THERAPEUTICS LTD** [GB/GB]; Stevenage Bioscience Catalyst, Accelerator Building, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Angel Building, 407 St John Street, London EC1V 4AD (GB).

(72) Inventors: **GOUBIER, Anne**; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **MERCHIERS, Pascal**; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **SALIMU, Josephine**; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **GOYENECHEA, Beatriz**; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **MOULDER, Kevin**; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **QUEZADA, Sergio**; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). **PEGGS, Karl**; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). **VARGAS, Fred Arce**; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB). **SOLOMON, Isabelle**; c/o Cancer Research Technology Limited, Angel Building, 407 St John Street, London Greater London EC1V 4AD (GB).

(74) Agent: **LEONARD, Thomas Charles**; Kilburn & Strode LLP, Lacon London, 84 Theobalds Road, London London WC1X 8NL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2018/167104 A1

(54) Title: FC-OPTIMIZED ANTI-CD25 FOR TUMOUR SPECIFIC CELL DEPLETION

(57) Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2 - CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.